

Andrea Sartore-Bianchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7554181/publications.pdf>

Version: 2024-02-01

191
papers

26,149
citations

26567

56
h-index

6454

157
g-index

199
all docs

199
docs citations

199
times ranked

25144
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. <i>Science Translational Medicine</i> , 2014, 6, 224ra24.	5.8	3,665
2	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. <i>Lancet Oncology</i> , The, 2010, 11, 753-762.	5.1	1,915
3	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. <i>Nature</i> , 2012, 486, 532-536.	13.7	1,605
4	Wild-Type <i>BRAF</i> Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 5705-5712.	0.8	1,540
5	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. <i>Lancet Oncology</i> , The, 2005, 6, 279-286.	5.1	924
6	A Molecularly Annotated Platform of Patient-Derived Xenografts (â€œXenopatientsâ€) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer. <i>Cancer Discovery</i> , 2011, 1, 508-523.	7.7	818
7	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. <i>Nature Medicine</i> , 2015, 21, 795-801.	15.2	809
8	Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Antiâ€œEpidermal Growth Factor Receptor Antibody Therapies. <i>Cancer Research</i> , 2007, 67, 2643-2648.	0.4	801
9	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 738-746.	5.1	778
10	<i>PIK3CA</i> Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies. <i>Cancer Research</i> , 2009, 69, 1851-1857.	0.4	711
11	Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1812.	3.8	663
12	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer Discovery</i> , 2017, 7, 400-409.	7.7	647
13	Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. <i>Cancer Discovery</i> , 2013, 3, 658-673.	7.7	585
14	Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptorâ€œTargeted Therapy in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1308-1324.	3.0	486
15	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. <i>Nature</i> , 2017, 552, 116-120.	13.7	480
16	NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. <i>ESMO Open</i> , 2016, 1, e000023.	2.0	444
17	Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution. <i>Cancer Discovery</i> , 2014, 4, 1269-1280.	7.7	415
18	The genomic landscape of response to EGFR blockade in colorectal cancer. <i>Nature</i> , 2015, 526, 263-267.	13.7	398

#	ARTICLE	IF	CITATIONS
19	Early-onset colorectal cancer in young individuals. <i>Molecular Oncology</i> , 2019, 13, 109-131.	2.1	365
20	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. <i>Cancer Discovery</i> , 2016, 6, 147-153.	7.7	338
21	Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab. <i>Journal of Clinical Oncology</i> , 2007, 25, 3238-3245.	0.8	321
22	Adaptive mutability of colorectal cancers in response to targeted therapies. <i>Science</i> , 2019, 366, 1473-1480.	6.0	290
23	Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. <i>Cancer Discovery</i> , 2016, 6, 36-44.	7.7	258
24	The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. <i>Nature Communications</i> , 2015, 6, 7002.	5.8	251
25	Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer. <i>PLoS ONE</i> , 2009, 4, e7287.	1.1	241
26	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 779-789.	5.1	234
27	Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer. <i>Science Translational Medicine</i> , 2014, 6, 224ra26.	5.8	228
28	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. <i>Modern Pathology</i> , 2015, 28, 1481-1491.	2.9	226
29	Mutations of <i>KRAS</i> and <i>BRAF</i> in Primary and Matched Metastatic Sites of Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4217-4219.	0.8	218
30	Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. <i>Gut</i> , 2018, 67, 1995-2005.	6.1	188
31	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	183
32	Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. <i>Annals of Oncology</i> , 2018, 29, 1108-1119.	0.6	177
33	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. <i>Nature Communications</i> , 2016, 7, 13665.	5.8	170
34	KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. <i>International Journal of Cancer</i> , 2013, 133, 1259-1265.	2.3	154
35	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. <i>Annals of Oncology</i> , 2015, 26, 2092-2097.	0.6	137
36	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. <i>Cancer Cell</i> , 2018, 34, 148-162.e7.	7.7	129

#	ARTICLE	IF	CITATIONS
37	The TPM3&NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. <i>Molecular Oncology</i> , 2014, 8, 1495-1507.	2.1	128
38	Acquired resistance to EGFR&Etargeted therapies in&colorectal cancer. <i>Molecular Oncology</i> , 2014, 8, 1084-1094.	2.1	121
39	Plasma HER2 (<i>ERBB2</i>) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3046-3053.	3.2	112
40	Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	111
41	Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. <i>Clinical Colorectal Cancer</i> , 2017, 16, e153-e163.	1.0	110
42	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015, 26, 1994-1999.	0.6	105
43	Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 2265-2272.	3.2	96
44	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1395-1402.	1.9	95
45	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. <i>ESMO Open</i> , 2020, 5, e000911.	2.0	94
46	The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. <i>British Journal of Cancer</i> , 2020, 123, 403-409.	2.9	93
47	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in <i>BRAF</i>-Mutant Colorectal Cancer. <i>Cancer Research</i> , 2016, 76, 4504-4515.	0.4	91
48	Bortezomib Inhibits Nuclear Factor- κ B&E“Dependent Survival and Has Potent In vivo Activity in Mesothelioma. <i>Clinical Cancer Research</i> , 2007, 13, 5942-5951.	3.2	90
49	Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt322.	3.0	76
50	Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2018, 29, 119-126.	0.6	76
51	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1268.	3.4	70
52	Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. <i>Cancer Treatment Reviews</i> , 2019, 73, 41-53.	3.4	69
53	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. <i>Clinical Cancer Research</i> , 2020, 26, 1372-1384.	3.2	66
54	Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. <i>British Journal of Cancer</i> , 2015, 113, 1730-1734.	2.9	65

#	ARTICLE	IF	CITATIONS
55	Negative Hyperselection of Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 3099-3110.	0.8	65
56	The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. <i>Annals of Oncology</i> , 2020, 31, 1135-1147.	0.6	58
57	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 256-262.e2.	1.0	56
58	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of <i>KRAS</i> Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 3657-3666.	3.2	53
59	A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell "Intrinsic Transcriptional MSI Traits. <i>Cancer Research</i> , 2019, 79, 5884-5896.	0.4	53
60	Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. <i>Clinical Colorectal Cancer</i> , 2019, 18, e117-e129.	1.0	53
61	Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3506-3506.	0.8	53
62	Raltitrexed "Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. <i>Lung Cancer</i> , 2005, 48, 429-434.	0.9	51
63	Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. <i>Annals of Oncology</i> , 2016, 27, 1456-1466.	0.6	51
64	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the "BRAF BeCool" study. <i>European Journal of Cancer</i> , 2019, 118, 121-130.	1.3	51
65	The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. <i>Drugs</i> , 2019, 79, 1375-1394.	4.9	48
66	Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair "Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy. <i>Cancer Discovery</i> , 2021, 11, 1923-1937.	7.7	48
67	Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. <i>Cancer Discovery</i> , 2022, 12, 1656-1675.	7.7	48
68	The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 137.	1.7	46
69	Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ. <i>Nature Communications</i> , 2021, 12, 2340.	5.8	43
70	Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6243-6259.	3.2	42
71	EGFR FISH in colorectal cancer: what is the current reality?. <i>Lancet Oncology</i> , The, 2008, 9, 402-403.	5.1	41
72	Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. <i>British Journal of Cancer</i> , 2022, 127, 394-407.	2.9	41

#	ARTICLE	IF	CITATIONS
73	Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 80-83.	1.0	40
74	Strategies to tackle RAS-mutated metastatic colorectal cancer. <i>ESMO Open</i> , 2021, 6, 100156.	2.0	38
75	Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2010, 36, S1-S5.	3.4	37
76	Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression. <i>Nature Immunology</i> , 2021, 22, 735-745.	7.0	36
77	Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. <i>Journal of Clinical Pathology</i> , 2012, 65, 218-223.	1.0	35
78	Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, 1062-1067.	0.6	35
79	Increased incidence of colon cancer among individuals younger than 50 years: A 17 years analysis from the cancer registry of the municipality of Milan, Italy. <i>Cancer Epidemiology</i> , 2019, 60, 134-140.	0.8	34
80	CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6350.	1.8	34
81	The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives. <i>Cancer Treatment Reviews</i> , 2022, 104, 102351.	3.4	34
82	Tracking aCAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. <i>Annals of Oncology</i> , 2017, 28, 1302-1308.	0.6	32
83	Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. <i>Cancers</i> , 2021, 13, 2638.	1.7	32
84	Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study. <i>Clinical Colorectal Cancer</i> , 2016, 15, 213-221.	1.0	31
85	Prognostic significance of <i>K-Ras</i> mutation rate in metastatic colorectal cancer patients. <i>Oncotarget</i> , 2015, 6, 31604-31612.	0.8	30
86	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. <i>ESMO Open</i> , 2018, 3, e000299.	2.0	29
87	Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression. <i>Cancer Immunology Research</i> , 2019, 7, 751-758.	1.6	29
88	Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. <i>Cancer Treatment Reviews</i> , 2020, 91, 102112.	3.4	29
89	Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases. <i>European Radiology Experimental</i> , 2020, 4, 62.	1.7	29
90	Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer. <i>Annals of Oncology</i> , 2005, 16, 1848-1849.	0.6	28

#	ARTICLE	IF	CITATIONS
91	Liquid biopsy for rectal cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2019, 79, 101893.	3.4	28
92	Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. <i>Targeted Oncology</i> , 2010, 5, 19-28.	1.7	27
93	Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. <i>European Journal of Cancer</i> , 2017, 71, 43-50.	1.3	27
94	Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. <i>ESMO Open</i> , 2019, 4, e000572.	2.0	27
95	Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy. <i>International Journal of Cancer</i> , 2020, 147, 3215-3223.	2.3	27
96	Alka-372-001: First-in-human, phase I study of entrectinib an oral pan-trk, ROS1, and ALK inhibitor in patients with advanced solid tumors with relevant molecular alterations.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2517-2517.	0.8	27
97	Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3508-3508.	0.8	27
98	Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. <i>Cancer</i> , 2013, 119, 3429-3435.	2.0	26
99	Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 333-341.	1.1	26
100	Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT) <i>TJ ETQq0 0 0z gBT /Overbck 10 Tf</i>		
101	Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma. <i>Cancer</i> , 2004, 100, 2132-2138.	2.0	24
102	Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. <i>Cancer Treatment Reviews</i> , 2016, 51, 54-62.	3.4	24
103	Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System. <i>American Journal of Hypertension</i> , 2016, 29, 158-162.	1.0	23
104	First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3505-3505.	0.8	23
105	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Frontiers in Oncology</i> , 2019, 9, 622.	1.3	22
106	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1017-1024.	3.2	22
107	Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2013, 8, e62264.	1.1	21
108	Regorafenib in metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 255-265.	1.1	20

#	ARTICLE	IF	CITATIONS
109	Central Nervous System as Possible Site of Relapse in <i>ERBB2</i> -Positive Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 927.	3.4	20
110	Abstract CT005: Final results of the HERACLES trial in HER2-amplified colorectal cancer. <i>Cancer Research</i> , 2017, 77, CT005-CT005.	0.4	19
111	Optimal CD34+ Cell Dose in Autologous Peripheral-Blood Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2000, 18, 3319-3320.	0.8	18
112	Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. <i>Nature Communications</i> , 2018, 9, 2287.	5.8	18
113	Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2502-2502.	0.8	18
114	HER2 amplification as a \sim molecular bait [™] for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS774-TPS774.	0.8	18
115	The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review. <i>Frontiers in Oncology</i> , 2020, 10, 533.	1.3	17
116	Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment. <i>European Journal of Cancer</i> , 2022, 163, 16-25.	1.3	17
117	Human Epidermal Growth Factor Receptor 2 as a Molecular Biomarker for Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2018, 4, 19.	3.4	16
118	Regorafenib for metastatic colorectal cancer. <i>Lancet, The</i> , 2013, 381, 1537.	6.3	15
119	Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience. <i>Targeted Oncology</i> , 2017, 12, 525-533.	1.7	15
120	Pneumatosis Intestinalis Induced by Anticancer Treatment: A Systematic Review. <i>Cancers</i> , 2022, 14, 1666.	1.7	15
121	The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2505-2514.	3.2	14
122	Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA. <i>Targeted Oncology</i> , 2021, 16, 309-324.	1.7	14
123	Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis. <i>Cancers</i> , 2021, 13, 2265.	1.7	14
124	The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4124-TPS4124.	0.8	14
125	Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases. <i>Cancers</i> , 2022, 14, 241.	1.7	14
126	Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management. <i>ESMO Open</i> , 2022, 7, 100338.	2.0	14

#	ARTICLE	IF	CITATIONS
127	Magnetic Resonance Imaging as an Early Indicator of Clinical Outcome in Patients With Metastatic Colorectal Carcinoma Treated With Cetuximab or Panitumumab. <i>Clinical Colorectal Cancer</i> , 2013, 12, 45-53.	1.0	13
128	Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2018, 29, 2143-2144.	0.6	13
129	TRKA expression and <i>NTRK1</i> gene copy number across solid tumours. <i>Journal of Clinical Pathology</i> , 2018, 71, 926-931.	1.0	12
130	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. <i>European Journal of Cancer</i> , 2020, 135, 230-239.	1.3	11
131	Optimized EGFR Blockade Strategies in <i>EGFR</i> Addicted Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 3126-3140.	3.2	11
132	Cetuximab for treatment of metastatic colorectal cancer. <i>Annals of Oncology</i> , 2006, 17, vii66-vii67.	0.6	10
133	Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast. <i>Journal of Clinical Oncology</i> , 2016, 34, e54-e56.	0.8	10
134	Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS2659-TPS2659.	0.8	10
135	Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study. <i>Cancers</i> , 2022, 14, 1197.	1.7	9
136	Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: A possible mechanism of interleukin-2-mediated cytotoxicity?. <i>Lung Cancer</i> , 2002, 38, 159-162.	0.9	8
137	Plasma HER2 (ERBB2) copy number to predict response to HER2-targeted therapy in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3506-3506.	0.8	8
138	ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series. <i>JCO Precision Oncology</i> , 2022, 6, e2200015.	1.5	8
139	Breaking Barriers in HER2+ Cancers. <i>Cancer Cell</i> , 2020, 38, 317-319.	7.7	7
140	Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectal Cancer Enhanced Stratification).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS3648-TPS3648.	0.8	7
141	Abstract A089: Exploiting clonal evolution and liquid biopsy to overcome resistance to anti-EGFR treatment in metastatic colorectal cancer: the CHRONOS trial. , 2018, , ,		7
142	Personalized therapeutic strategies in HER2-driven gastric cancer. <i>Gastric Cancer</i> , 2021, 24, 897-912.	2.7	6
143	Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?. <i>British Journal of Cancer</i> , 2022, 127, 957-967.	2.9	6
144	Controversial evaluation of EGFR protein and gene status in predicting response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer: a case report and review of the literature. <i>Targeted Oncology</i> , 2008, 3, 127-130.	1.7	5

#	ARTICLE	IF	CITATIONS
145	Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids. <i>JCO Precision Oncology</i> , 2021, 5, 1192-1199.	1.5	5
146	Abstract 5723: Inactivation of DNA repair triggers neoantigen generation and impairs tumor growth. <i>Cancer Research</i> , 2018, 78, 5723-5723.	0.4	5
147	Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients. <i>Oncology Reports</i> , 2005, 13, 689-95.	1.2	5
148	Application of histology-agnostic treatments in metastatic colorectal cancer. <i>Digestive and Liver Disease</i> , 2022, 54, 1291-1303.	0.4	5
149	Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer. <i>Annals of Oncology</i> , 2006, 17, ii49-ii51.	0.6	4
150	Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET). <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 114-116.	0.7	4
151	Concurrent Small-Cell Transformation and Emergence of <i>Trans</i> -C797S and T790M Mutations Under Sequential Treatment With EGFR Inhibitors in Lung Adenocarcinoma. <i>JCO Precision Oncology</i> , 2019, 3, 1-5.	1.5	4
152	Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?. <i>Annals of Translational Medicine</i> , 2013, 1, 12.	0.7	4
153	Germ Cell Tumors Overexpress the Candidate Therapeutic target Cyclin B1 Independently of p53 function. <i>International Journal of Biological Markers</i> , 2015, 30, 275-281.	0.7	3
154	Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer. <i>ESMO Open</i> , 2016, 1, e000079.	2.0	3
155	Abstract CT082: Pertuzumab and trastuzumab-emtansine in HER2-positive colorectal cancer: the HERACLES B trial. , 2016, , .		3
156	Clinicopathological characteristics and HER2 status in metastatic colorectal cancer patients: Results of a diagnostic model development study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 581-581.	0.8	3
157	Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients. <i>Oncology Reports</i> , 0, , .	1.2	3
158	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with <i>RAS</i> Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study. <i>Oncologist</i> , 2022, 27, e29-e36.	1.9	3
159	Pertuzumab and trastuzumab-emtansine in HER2 positive metastatic colorectal cancer: the HERACLES B TRIAL. <i>Annals of Oncology</i> , 2016, 27, iv47.	0.6	2
160	507P Central nervous system recurrence in HER2-positive metastatic colorectal cancer. <i>Annals of Oncology</i> , 2020, 31, S455.	0.6	2
161	Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 565-565.	0.8	2
162	Clinical prognostic score of BRAF V600E mutated (BM) metastatic colorectal cancer (mCRC): Results from the <i>BRACON</i> platform.. <i>Journal of Clinical Oncology</i> , 2018, 36, 639-639.	0.8	2

#	ARTICLE	IF	CITATIONS
163	Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients. <i>Oncology Reports</i> , 2004, 12, 855-9.	1.2	2
164	Response: Re: Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2010, 102, 573-575.	3.0	1
165	Is Codon 13 KRAS Mutation Biologically Different from Codon 12 Mutation?. <i>Current Colorectal Cancer Reports</i> , 2012, 8, 272-276.	1.0	1
166	Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 145-159.	0.9	1
167	Molecular Markers Beyond Microsatellite Instability for Assessing Prognosis in Early-Stage Colorectal Cancer. <i>JAMA Oncology</i> , 2017, 3, 481.	3.4	1
168	The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1510.	3.4	1
169	Relationships Between Ktine Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, , .	1.0	1
170	Abstract 878: Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. , 2016, , .		1
171	Phase II study of temozolomide (TMZ) in metastatic colorectal cancer (mCRC) patients molecularly selected by MGMT promoter hypermethylation.. <i>Journal of Clinical Oncology</i> , 2015, 33, 583-583.	0.8	1
172	A randomized phase II trial of second-line CAPTEM versus FOLFIRI in <i>MGMT</i> methylated, <i>RAS</i> mutated metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3509-3509.	0.8	1
173	Abstract 2848: Radiographic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer. , 2018, , .		1
174	Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients. <i>European Journal of Cancer</i> , 2022, 167, 175-176.	1.3	1
175	Epidermal Growth Factor Receptor-Targeted Therapy of Colorectal Cancer with Panitumumab. <i>Current Cancer Therapy Reviews</i> , 2007, 3, 249-254.	0.2	0
176	The FUNNEL: a precision medicine project for metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, iv48.	0.6	0
177	The right chance for temozolomide in metastatic colorectal cancer?. <i>Annals of Oncology</i> , 2018, 29, 1618-1619.	0.6	0
178	SP-0453 Targeting DNA repair to improve immunesurveillance and restrict cancer growth. <i>Radiotherapy and Oncology</i> , 2019, 133, S235-S236.	0.3	0
179	Low doses of subcutaneous interleukin-2 plus interferon-Î± do not induce thyroid function alterations in advanced renal cell carcinoma patients. <i>Oncology Reports</i> , 0, , .	1.2	0
180	Abstract 2829: Identification of the role of SRBC methylation-associated gene silencing as predictive factor of oxaliplatin secondary resistance in metastatic colorectal cancer patients. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
181	The FUNNEL: A molecular multiplex triage for precision medicine in metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, TPS3636-TPS3636.	0.8	0
182	Abstract 3834: Tracking CAD-ALK gene translocation in urine and plasma of a colorectal cancer patient treated with ALK blockade. , 2017, , .		0
183	Abstract 2913: Emergence ofRASorEGFRmutant clones affects duration of response to EGFR blockade in colorectal cancers. , 2017, , .		0
184	Abstract A087: Empowering precision medicine in metastatic colorectal cancer: preliminary results from the FUNNEL platform. , 2018, , .		0
185	Abstract 2743: Accumulation of predicted neoantigens by MMR deficiency triggered by temozolomide treatment of human colorectal cancer. , 2018, , .		0
186	Abstract 205: Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. , 2018, , .		0
187	Mutational signatures of early-onset colorectal cancer.. Journal of Clinical Oncology, 2019, 37, e15113-e15113.	0.8	0
188	Radiomics features on CT scans to predict response to HER2-targeted therapy of hepatic metastases from colorectal cancer.. Journal of Clinical Oncology, 2019, 37, e15086-e15086.	0.8	0
189	Abstract LB-299: A comprehensive platform of patient-derived xenografts and matched cell lines mirrors the genomic landscape of colorectal cancer. , 2019, , .		0
190	Abstract A120: Adaptive mutability of colorectal cancers in response to targeted therapies. , 2019, , .		0
191	Efficacy of retreatment with oxaliplatin-based regimens in metastatic colorectal cancer patients: The RETROX-CRC retrospective study.. Journal of Clinical Oncology, 2022, 40, 127-127.	0.8	0